UY3901U - Placa electronica para sistema de monitoreo y gestion de vehiculos - Google Patents

Placa electronica para sistema de monitoreo y gestion de vehiculos

Info

Publication number
UY3901U
UY3901U UY3901U UY3901U UY3901U UY 3901 U UY3901 U UY 3901U UY 3901 U UY3901 U UY 3901U UY 3901 U UY3901 U UY 3901U UY 3901 U UY3901 U UY 3901U
Authority
UY
Uruguay
Prior art keywords
management system
vehicle monitoring
electronic plate
vehicle
gps
Prior art date
Application number
UY3901U
Other languages
English (en)
Inventor
Raul Fermin Pieri De Lo Santos
Original Assignee
Marenet S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marenet S A filed Critical Marenet S A
Publication of UY3901U publication Critical patent/UY3901U/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Position Fixing By Use Of Radio Waves (AREA)

Abstract

Modelo de placa electrónica destinada a un equipo o sistema de monitoreo o gerenciamiento de vehículos o flota de vehículos basado en el concepto de inteligencia distribuida, combinando software, hardware y firmware, desarrollado íntegralmente para soportar actividades de localización automática de vehículos mediante GPS y comunicación de datos sobre una gran variedad de redes de cumunicaciones inalámbricas.
UY3901U 2001-06-06 2002-05-29 Placa electronica para sistema de monitoreo y gestion de vehiculos UY3901U (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01113792 2001-06-06

Publications (1)

Publication Number Publication Date
UY3901U true UY3901U (es) 2002-07-31

Family

ID=8177653

Family Applications (2)

Application Number Title Priority Date Filing Date
UY3901U UY3901U (es) 2001-06-06 2002-05-29 Placa electronica para sistema de monitoreo y gestion de vehiculos
UY27320A UY27320A1 (es) 2001-06-06 2002-06-05 Nuevas composiciones farmacéuticas

Family Applications After (1)

Application Number Title Priority Date Filing Date
UY27320A UY27320A1 (es) 2001-06-06 2002-06-05 Nuevas composiciones farmacéuticas

Country Status (21)

Country Link
US (1) US6730319B2 (es)
EP (1) EP1399153B1 (es)
JP (1) JP4558313B2 (es)
KR (1) KR100613946B1 (es)
CN (1) CN1514726B (es)
AR (1) AR037490A1 (es)
AT (1) ATE375155T1 (es)
AU (1) AU2002319189B2 (es)
BR (1) BR0210267A (es)
CA (1) CA2448035C (es)
DE (1) DE60222898T2 (es)
DK (1) DK1399153T3 (es)
ES (1) ES2292782T3 (es)
GT (1) GT200200105A (es)
MX (1) MXPA03011041A (es)
PA (1) PA8546501A1 (es)
PE (1) PE20030262A1 (es)
PT (1) PT1399153E (es)
UY (2) UY3901U (es)
WO (1) WO2002098413A2 (es)
ZA (1) ZA200309099B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6616942B1 (en) * 1999-03-29 2003-09-09 Soft Gel Technologies, Inc. Coenzyme Q10 formulation and process methodology for soft gel capsules manufacturing
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
WO2001034119A2 (en) * 1999-11-12 2001-05-17 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
DE10026698A1 (de) * 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US8663687B2 (en) * 2001-10-12 2014-03-04 Monosol Rx, Llc Film compositions for delivery of actives
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
WO2003041632A2 (en) 2001-11-14 2003-05-22 Texas Tech University Eutectic-based self-nanoemulsified drug delivery system
US8372430B2 (en) * 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
ES2234393B2 (es) * 2003-04-29 2006-09-01 Laboratorios Belmac, S.A. "formulaciones de pelets de compuestos bencimidazolicos antiulcerosos y labiles al acido".
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
WO2005026140A1 (en) * 2003-09-12 2005-03-24 Ranbaxy Laboratories Limited Process for the preparation of crystalline forms of orlistat
US8105583B2 (en) * 2003-09-29 2012-01-31 Soft Gel Technologies, Inc. Solubilized CoQ-10
US8124072B2 (en) 2003-09-29 2012-02-28 Soft Gel Technologies, Inc. Solubilized CoQ-10
JP4954450B2 (ja) * 2004-06-14 2012-06-13 ビーエーエスエフ ビューティ ケア ソリューションズ フランス エスエーエス 弾性繊維形成の不全、欠損又は無秩序による病状に対処するための、リシルオキシダーゼのアイソフォームの活性の誘導
KR100669497B1 (ko) * 2005-08-17 2007-01-16 보람제약주식회사 안정성과 용출률이 뛰어난 약리학적 조성물 및 그 제조방법
WO2008000440A1 (en) * 2006-06-27 2008-01-03 Lipid Nutrition B.V. Use of a polyunsaturated fatty acid compound
US8343541B2 (en) 2007-03-15 2013-01-01 Soft Gel Technologies, Inc. Ubiquinol and alpha lipoic acid compositions
BRPI0817053A2 (pt) * 2007-09-17 2015-03-24 Reddys Lab Ltd Dr Formulações farmacêuticas de orlistat
EP2219614A1 (en) * 2007-10-15 2010-08-25 Inventis DDS Pvt Limited Pharmaceutical composition of orlistat
US8298583B2 (en) * 2007-10-19 2012-10-30 Monosol Rx, Llc Film delivery system for tetrahydrolipstatin
PL216542B1 (pl) 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
KR200449701Y1 (ko) * 2008-08-21 2010-08-02 한복순 월풀욕조의 잔물 제거장치
US8309107B2 (en) * 2008-10-06 2012-11-13 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
BRPI0901602B8 (pt) 2009-04-03 2021-05-25 Ems S/A formulação farmacêuticas
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
KR101593539B1 (ko) * 2015-07-03 2016-02-15 고려대학교 산학협력단 지방조직 중성지질 분해 효능을 가지는 아젤라산 조성물
CN109310646A (zh) 2016-05-05 2019-02-05 阿奎斯蒂弗医疗股份有限公司 增强递送的肾上腺素组合物
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
US10786475B2 (en) 2018-02-20 2020-09-29 Korea University Research And Business Foundation Method for preventing, treating, or improving fatty liver by administering effective amounts of azelaic acid to a subject
US11931330B2 (en) 2018-02-20 2024-03-19 Korea University Research And Business Foundation Composition for promoting skeletal muscle activity via induction of mitochondrial biogenesis comprising of azelaic acid as an active ingredient
CN108354910A (zh) * 2018-05-17 2018-08-03 安士制药（中山）有限公司 一种西甲硅油软胶囊
CN113163815A (zh) * 2018-12-06 2021-07-23 国际香料和香精公司 用于调节味道的苎麻组合物和方法
WO2020118005A1 (en) * 2018-12-06 2020-06-11 International Flavors & Fragrances Inc. Traumatic acid compositions and methods for taste modulation
WO2021023857A1 (en) * 2019-08-08 2021-02-11 Evonik Operations Gmbh Solubility enhancement of poorly soluble actives

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3013839A1 (de) 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
DE3217071A1 (de) 1982-05-06 1983-11-10 Rüdiger Dr. 6365 Rosbach Gröning Arzneimittel fuer die perorale applikation mit verbesserter biologischer verfuegbarkeit der wirkstoffe
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
CA1270837A (en) 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
CA2035972C (en) 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
FI912955A (fi) 1990-06-25 1991-12-26 Res Found Mental Hygiene Antimikroba fettsyrasammansaettningar.
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
JP2682353B2 (ja) * 1991-11-20 1997-11-26 武田薬品工業株式会社 経口用医薬組成物およびその製造法
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
JPH1081621A (ja) * 1996-04-01 1998-03-31 Takeda Chem Ind Ltd 経口投与用医薬組成物
DE19739031A1 (de) 1997-09-05 1999-03-11 Suwelack Nachf Dr Otto Mittel zur peroralen Verabreichung, seine Herstellung und Verwendung
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
JP3774118B2 (ja) 1998-08-14 2006-05-10 エフ．ホフマン−ラ ロシュ アーゲー リパーゼ阻害剤を含む製薬学的組成物
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
AR025609A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
AR025587A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
US6348492B1 (en) 1999-10-29 2002-02-19 2Pro Chemical Oxetanone derivatives
CA2358921A1 (en) 1999-10-29 2001-05-10 John Jason Gentry Mullins Oxetanone derivatives
MXPA02004504A (es) * 1999-11-04 2002-09-02 Monsanto Technology Llc Composiciones de esterol que reducen colesterol, preparacion y metodo de uso.

Also Published As

Publication number Publication date
KR100613946B1 (ko) 2006-08-18
WO2002098413A3 (en) 2003-02-27
US20030039686A1 (en) 2003-02-27
PT1399153E (pt) 2007-12-31
DK1399153T3 (da) 2008-01-07
PE20030262A1 (es) 2003-03-19
ES2292782T3 (es) 2008-03-16
GT200200105A (es) 2003-02-26
MXPA03011041A (es) 2004-03-19
AR037490A1 (es) 2004-11-17
ATE375155T1 (de) 2007-10-15
CN1514726A (zh) 2004-07-21
KR20040010681A (ko) 2004-01-31
WO2002098413A2 (en) 2002-12-12
EP1399153A2 (en) 2004-03-24
UY27320A1 (es) 2003-02-28
DE60222898T2 (de) 2008-07-24
EP1399153B1 (en) 2007-10-10
AU2002319189B2 (en) 2005-08-18
US6730319B2 (en) 2004-05-04
PA8546501A1 (es) 2003-01-24
DE60222898D1 (de) 2007-11-22
CA2448035C (en) 2009-11-03
CN1514726B (zh) 2010-10-06
CA2448035A1 (en) 2002-12-12
ZA200309099B (en) 2005-05-25
BR0210267A (pt) 2004-07-20
JP2004532272A (ja) 2004-10-21
JP4558313B2 (ja) 2010-10-06

Similar Documents

Publication Publication Date Title
UY3901U (es) Placa electronica para sistema de monitoreo y gestion de vehiculos
WO2006130346A3 (en) Medical alert communication systems and methods
ATE522896T1 (de) Containerverfolgungssystem
ATE470324T1 (de) System für autonomen anwendungsserver-zugriff üebr verschiedene arten von zugriffstechnologienetzwerken hinweg
DK1565998T3 (da) Effekstyring i ydre sløjfe til trådløse kommunikationssystemer
ATE499813T1 (de) Kommunikationsnetz
ZA200309769B (en) Positional information management system.
TWI265405B (en) Dynamic power management
BR0312488A (pt) Método e sistema para transmitir informações a usuários de um sistema logìstico
EG24960A (en) Distributed beaconing periods for ad-hoc networks.
WO2006093917A3 (en) Mobile data security system and methods
WO2002061998A3 (en) Access parameter adaptation and packet data resource management using detailed mobile status information
AR049272A1 (es) Sistema y metodo para ejecutar una transmision independiente de los medios
AU2003238902A8 (en) Systems and methods for providing business intelligence based on shipping information
DK1256188T3 (da) Tilgangskanalstruktur for trådlöst kommunikationssystem
US10796213B2 (en) Method and apparatus for providing a communications service using a low powered radio tag
EP1531561A4 (en) POSITIONS MANAGEMENT SERVER AND MOBILE COMMUNICATION SYSTEM
ZA200309773B (en) Positional information management system.
SE0200827D0 (sv) Lock system, lock system device and method of configuring a lock system
DE60038933D1 (de) Datenverwaltungssystem mit mehreren Datenbetriebsmodulen
NO20034746L (no) Fremgangsmate og tilgangssted for a levere informasjon til mobile innretninger
WO2006050522A3 (en) Modular intelligent transportation system
FR2871967B1 (fr) Module d'echange d'informations par courants porteurs et procede de gestion du fonctionnement de ce module
NO20056179L (no) Fremgangsmate, styring og datamaskinprogramvare for styring av kommunikasjonsressurser
DE69738216D1 (de) Informationsverbindung

Legal Events

Date Code Title Description
105 Application deemed to be withdrawn (no grant fee paid)

Effective date: 20140905